Argatroban Plus R-tPA for Acute Ischemic Stroke
Argatroban Plus R-tPA for Acute Ischemic Stroke
Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of
 morbidity, mortality and disability. A large number of studies have confirmed that the
 thrombolytic therapy can effectively open blood vessels and improve the functional prognosis
 of acute ischemic stroke. Therefore, all guidelines recommend intravenous thrombolysis as the
 first treatment of ischemic stroke patients within 4.5 hours of onset. However, about 1/3
 patients receiving thrombolysis will have good prognosis, while a large number of patients
 will still be disabled and even dead. How to improve the neurological prognosis of
 thrombolytic patients has been a hot topic in the world.

 Recent studies have found that the combined application of argatroban and rt-PA in the
 treatment of AIS might improve the clinical prognosis and not significantly increase
 bleeding. Some studies have reported that the combined application of argatroban and rt-PA
 could improve the blood vessel opening rate, and prevent re-occlusion after opening.

 Based on the discussion, the present study is designed to explore the efficacy and safety of
 argatroban plus rt-PA in the treatment of AIS.
Inclusion Criteria:

 1. 18-80 years old;

 2. Time from onset to treatment ≤4.5 hours;

 3. NIHSS ≥ 6

 4. Diagnosis of ischemic stroke

 5. Signed informed consent by patient self or legally authorized representatives.

 Exclusion Criteria:

 1. mRS≥2;

 2. History of stroke within 3 months;

 3. History of intracranial hemorrhage;

 4. Suspected subarachnoid hemorrhage;

 5. Intracranial tumour, vascular malformation or arterial aneurysm;

 6. Major surgery within 1 month;

 7. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;

 8. Platelet count < 105/mm3;

 9. Heparin therapy or oral anticoagulation therapy within 48 hours;

 10. Abnormal APTT;

 11. Thrombin or Xa factor inhibitor;

 12. Severe disease with a life expectancy of less than 3 months;

 13. Blood glucose < 50 mg/dL (2.7mmol/L);

 14. Patients who have received any other investigational drug or device within 3 months;

 15. Pregnancy;

 16. Researchers consider patients inappropriate to participate in the registry.